Teva gets more than half of U.S. Copaxone patients converted to long-lasting version

Eric Palmer One of the key strategies being pursued by Teva Pharmaceutical Industries to protect itself against generic competition to Copaxone is to switch patients over to its new ...

Merck KGaA brings on U.S. Merck’s Rossetti to head R&D

Michael Gibney FierceBiotech News

GlaxoSmithKline pulls all U.S. alli supplies, launches product-tampering probe

Carly Helfand GlaxoSmithKline is recalling supplies of its OTC weight-loss drug alli in light of reports from U.S. consumers who found the wrong drug when they opened their bottles. FiercePharma ...

U.S. rep rips the FDA’s efforts to speed up drug approvals

Damian Garde Over the past few years, the FDA has unveiled a spate of new approval pathways in hopes of getting much-needed treatments on the market faster. But in the rush to accelerate ...

Ranbaxy will need new markets as FDA closes window on U.S., analysts predict

Eric Palmer What is a generic drugmaker going to do when the FDA finds flies filling its analytics laboratory and shuts down a yet another plant key to serving the U.S. market? Start ...

Ariad storms back with an FDA nod to get Iclusig back on the U.S. market

Damian Garde Losing more than $ 2.5 billion in market value didn't kill Ariad Pharmaceuticals, and now the biotech is set to relaunch the once-spurned cancer drug Iclusig in the ...

U.S. access group aims to block Indian patent for Gilead’s hot hep C drug

Tracy Staton Gilead Sciences' new hepatitis C drug sofosbuvir won preliminary backing from European regulators on Friday, with marketing approval expected to follow soon. The FDA ...

FDA approves GSK bird flu vaccine for U.S. stockpile

Eric Palmer The FDA has approved its first adjuvanted vaccine against a potential outbreak of the deadly bird flu. It just won't be available at the local pharmacy. FiercePharma ...

Actavis cutting 30% of U.S. sales organization

Eric Palmer Actavis began tallying up just how many bodies it needed in its U.S. sales organization as soon as it closed Oct. 1 on its $ 8.5 billion merger with Warner Chilcott.  FiercePharma ...

Repligen Completes Expansion of U.S. Manufacturing Facility

mia.burns WALTHAM, MA – November 1, 2013 – Repligen Corporation today announced it has completed a 9,000 square foot expansion of its manufacturing facilities at its Waltham ...

Drug use, spending varies widely in U.S. by region

Carly Helfand As the government searches for ways to limit Medicare spending, it may eye a new report that says in some regions, older patients don't get the drugs they need–and ...

How do U.S. drugs come to cost more? Let us count the ways

Tracy Staton Why the disparity in drug prices? It's a question asked repeatedly, and the specific answers are multifarious and complex.  FiercePharma News
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS